Specifically, the patent on GS-441524 dates to around 2009, compared with remdesivir about five years later, meaning that Gilead has exclusive rights to produce remdesivir further into the future. Remdesivir is an expensive drug, priced at $390 per dose, which comes to $2,340 for each patient treated over the course of five days.
In search for COVID-19 treatments, consumer group pushes drugmaker Gilead to test alternative to remdesivir
Prepare Now Before its too Late
Discover where products are available & compare prices
